Axsome Therapeutics is a biopharmaceutical company that develops therapies for the management and treatment of neurological disorders.
Axsome Therapeutics has raised $570.0M in total funding. The most recent round was Post-IPO Debt. The last funding was announced in May 2025.
Axsome Therapeutics's investors include Blackstone Group, Hercules Capital.
Axsome Therapeutics is headquartered in New York, United States.
Axsome Therapeutics is a biopharmaceutical company that develops therapies for the management and treatment of neurological disorders.
Axsome Therapeutics is at the Post-IPO Debt stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Axsome Therapeutics — Funding & Investors." VCBacked, May 13, 2025, https://www.vcbacked.co/company/axsome-therapeutics. Accessed August 14, 2026.
VCBacked. (2025). Axsome Therapeutics — Funding & Investors. Retrieved August 14, 2026, from https://www.vcbacked.co/company/axsome-therapeutics
{{cite web |title=Axsome Therapeutics — Funding & Investors |url=https://www.vcbacked.co/company/axsome-therapeutics |website=VCBacked |access-date=August 14, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated